NANOVIRICIDES, INC. NNVC
On September 25, 2013, the Company's common stock began trading on the New York Stock Exchange American under the symbol, "NNVC".
We are a clinical stage company with our first drug ready to enter Phase II human clinical efficacy trial, having successfully completed Phase Ia/Ib human clinical safety and tolerability trial. Based on our nanoviricides™ platform technology, we also have several additional drug candidates in various stages of pre-clinical development, including IND-filing stage and late stage IND-enabling non-clinical studies. We have no customers, products or revenues to date, and may never achieve revenues or profitable operations.
We are engaged in developing a class of drugs, that we call nanoviricides™, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. This approach enables rapid development of effective new drugs against a number of different viruses, that the viruses are highly unlikely to escape even as they evolve rapidly in the field, solving an important problem in attacking viruses. The virus evolution is known to generate viruses that escape the traditional antiviral approaches vaccines, antibodies and small chemical drugs.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — | — | — | — | — | — | — |
| R&D | $5.5M | $5.4M | $6.4M | $5.8M | $6.1M | $4.7M | $5.9M | $5.9M | $6.6M | $5.0M |
| SG&A | $4.0M | $3.1M | $2.6M | $2.3M | $2.6M | $3.3M | $2.7M | $3.4M | $3.0M | $3.8M |
| Total operating expenses | $9.6M | $8.5M | $8.9M | $8.1M | $8.7M | $8.0M | $8.7M | $9.3M | $9.6M | $8.9M |
| Operating income | -$9.6M | -$8.5M | -$8.9M | -$8.1M | -$8.7M | -$8.0M | -$8.7M | -$9.3M | -$9.6M | -$8.9M |
| Interest expense | $149 | $49.8K | $938 | $5.1K | $85.4K | $93.7K | $0 | $185.3K | $780.8K | $1.0M |
| Pre-tax income | — | — | — | -$8.1M | -$8.8M | -$13.4M | -$8.4M | -$8.6M | -$10.3M | -$10.7M |
| Income tax | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Net income | -$9.5M | -$8.3M | -$8.6M | -$8.1M | -$8.8M | -$13.4M | -$8.4M | -$8.6M | -$10.3M | -$10.7M |
| EPS, basic | -0.63 | -0.70 | -0.74 | -0.70 | -0.81 | — | — | -0.13 | -0.17 | -0.19 |
| EPS, diluted | -0.63 | -0.70 | -0.74 | -0.70 | -0.81 | -2.39 | -2.35 | -2.64 | -0.17 | -0.19 |
| Shares, diluted (wtd. avg.) | $15.1M | $11.9M | $11.6M | $11.5M | $10.9M | — | — | $64.9M | $60.1M | $57.7M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.6M | $4.8M | $8.1M | $14.1M | $20.5M | $13.7M | $2.6M | $7.1M | $15.1M | $24.2M |
| Total current assets | $1.7M | $5.0M | $8.4M | $14.4M | $20.8M | $14.0M | $2.8M | $7.3M | $15.3M | $24.4M |
| Property, plant and equipment | $6.8M | $7.5M | $8.1M | $8.7M | $9.1M | $9.5M | $10.2M | $10.8M | $11.3M | $11.8M |
| Other intangibles | $317.0K | $325.3K | $333.6K | $341.8K | $350.1K | $358.4K | $366.7K | $374.9K | $383.2K | $391.5K |
| Total assets | $8.8M | $12.8M | $16.9M | $23.5M | $30.3M | $23.9M | $13.4M | $18.5M | $27.0M | $36.6M |
| Short-term debt | — | — | — | — | — | — | — | — | — | $5.5M |
| Total current liabilities | $1.3M | $1.4M | $534.2K | $412.8K | $351.1K | $2.2M | $2.8M | $881.9K | $4.7M | $6.7M |
| Long-term debt | — | — | — | — | — | — | — | — | $4.7M | — |
| Total liabilities | $1.3M | $1.4M | $2.0M | $412.8K | — | — | — | $881.9K | $6.7M | $13.6M |
| Retained earnings | -$148.8M | -$139.4M | -$131.1M | -$122.5M | -$114.4M | -$105.6M | -$92.1M | -$83.7M | -$75.1M | -$64.8M |
| Total equity | $7.5M | $11.5M | $14.9M | $23.1M | $29.9M | $21.8M | $10.6M | $17.7M | $20.3M | $23.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.5M | -$6.3M | -$5.7M | -$5.9M | -$8.2M | -$6.7M | -$6.8M | -$7.8M | -$7.9M | -$6.8M |
| Depreciation and amortisation | $735.5K | $750.7K | $739.3K | $715.1K | $696.3K | $691.5K | $687.6K | $671.8K | $654.7K | $651.3K |
| Stock-based compensation | — | — | — | — | — | — | $35.8K | $156.2K | — | $158.0K |
| Capital expenditure | $57.0K | $156.6K | $151.7K | $324.3K | $238.8K | $8.6K | $73.8K | $241.8K | $165.0K | $476.4K |
| Investing cash flow | -$57.0K | -$156.6K | -$151.7K | -$324.3K | — | — | — | — | -$165.0K | -$476.4K |
| Financing cash flow | $5.3M | $3.1M | -$94.8K | -$234.7K | $15.3M | $17.8M | $2.4M | $0 | -$1.0M | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-25-094527.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |